Vtama in Psoriasis Patients Being Treated With Biologics.

Open Label, Observational Study, Evaluating VTAMA® (Tapinarof) Cream, 1% QD in Psoriasis Patients Being Treated With Biologic Agents.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06103695

Enrollment

Registered

2023-10-27

Start date

2023-02-27

Completion date

2023-10-18

Last updated

2023-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Brief summary

Open label study to assess 12 weeks of add-on VTAMA® (tapinarof) Cream, 1% QD in patients with ≥3% BSA who have received biologic therapy for at least 24 weeks.

Interventions

DRUGTapinarof

Add on Vtama (tapinarof) to biololgic therapy

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

open label

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Male or female adult ≥ 18 years of age; 2. Diagnosis of chronic plaque-type 3. Patient with ≥3% BSA 4. Patient has been treated with biologic for a minimum of 24 weeks 5. Able and willing to give written informed consent prior to performance of any study-related procedures.

Exclusion criteria

1. ≤3% BSA 2. Patient not receiving biologic agent, or receiving biologic agent \<24weeks

Design outcomes

Primary

Measure	Time frame	Description
Body surface area ≤1%	12 weeks	Patients who achieve body surface area of ≤1%

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026